Filtered By:
Infectious Disease: SARS
Countries: South Africa Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 93 results found since Jan 2013.
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
CONCLUSION: Amubarvimab plus romlusevimab was safe and significantly reduced the risk for hospitalization and/or death among nonhospitalized adults with mild to moderate SARS-CoV-2 infection at high risk for progression to severe disease.PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases of the National Institutes of Health.PMID:37068272 | DOI:10.7326/M22-3428
Source: Annals of Internal Medicine - April 17, 2023 Category: Internal Medicine Authors: Teresa H Evering Kara W Chew Mark J Giganti Carlee Moser Mauricio Pinilla David Alain Wohl Judith S Currier Joseph J Eron Arzhang Cyrus Javan Rachel Bender Ignacio David Margolis Qing Zhu Ji Ma Lijie Zhong Li Yan Ulises D'Andrea Nores Keila Hoover Bharat Source Type: research
What We Know So Far About the New Variant of COVID-19 Raising Alarms Globally
A new variant of SARS-CoV-2 first reported in South Africa is raising alarms for health officials around the world, leading to fresh travel restrictions amid fears it could be resistant to existing vaccines.
Researchers in South Africa conducting genetic analysis of COVID-19 virus cases determined that a new variant, B.1.1.529, had been found in cases in South Africa, Botswana, and a traveler who had traveled from South Africa to Hong Kong, the country’s health minister announced on Nov. 25. The following day, Belgian health officials reported the first case of the new variant discovered in Europe. That same day, the...
Source: TIME: Health - November 26, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
NEW BRUNSWICK, N.J., July 1, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The two preprint study summaries have been submitted today to bioRxiv. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help prot...
Source: Johnson and Johnson - July 1, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
The So-Called Delta Plus Variant of COVID-19 Is Dangerous But Appears Unlikely to Be a Game-Changer
As if the already worrisome Delta variant, first identified in India, wasn’t concerning enough, now there’s Delta Plus. The latest variant of SARS-CoV-2 was announced by Indian health officials in late June, and labelled by the Indian government as a variant of concern.
By June 24, only about 40 cases of Delta Plus infections were reported by Indian health officials, based on genetic sequencing of the virus from positive patients. But given the original Delta strain’s ability to transmit more efficiently from person to person, and to potentially cause more severe disease, health authorities are rightly ra...
Source: TIME: Health - June 25, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
The Delta Variant Could Soon Become the Dominant COVID-19 Strain. Here ’s What You Need to Know
The COVID-19 pandemic is increasingly becoming an arms race among the emerging variants of the virus, and at the moment, there’s no question which one is winning: the Delta variant—formally known as B.1.617.2—one of four strains to have emerged originally in India. It was just last month that the World Health Organization labeled Delta a “variant of concern”—joining with the Alpha strain, which emerged in the U.K.; the Beta strain, from South Africa; and the Gamma strain, first seen in Brazil. But Delta is fast becoming the most worrisome of the bunch.
Health officials are sounding the a...
Source: TIME: Science - June 15, 2021 Category: Science Authors: Alejandro de la Garza and Jeffrey Kluger Tags: Uncategorized COVID-19 Source Type: news
What We Learned About Genetic Sequencing During COVID-19 Could Revolutionize Public Health
You don’t want to be a virus in Dr. David Ho’s lab. Pretty much every day since the COVID-19 pandemic began, Ho and his team have done nothing but find ways to stress SARS-CoV-2, the virus that causes the disease. His goal: pressure the virus relentlessly enough that it mutates to survive, so drug developers can understand how the virus might respond to new treatments. As a virologist with decades of experience learning about another obstinate virus, HIV, Ho knows just how to apply that mutation-generating stress, whether by starving the virus, bathing it in antibodies that disrupt its ability to infect cells, ...
Source: TIME: Health - June 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 feature Genetics Magazine Source Type: news
COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases
S Afr Med J. 2021 Feb 8;111(4):291-294. doi: 10.7196/SAMJ.2021.v111i4.15576.ABSTRACTAs South Africa continues to battle the second wave of SARS-CoV-2 infections, the imminent arrival of vaccines against COVID-19 offers hope. Vaccine roll-out has been accompanied by heightened media coverage that has created both excitement and anxiety, reporting on the shortened timeline of vaccine trials and approvals, as well as the recent series of anaphylaxis cases associated with the two approved mRNA COVID-19 vaccines. Patients with allergic and other immune-based diseases are subgroups especially concerned about vaccine safety and e...
Source: South African Medical Journal - May 4, 2021 Category: African Health Authors: J Peter Source Type: research
